# Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

> **NCT07004413** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Charite University, Berlin, Germany** · enrollment: 267 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** FOLFIRI+cetuximab
- **DIAGNOSTIC_TEST:** Guardant360 ctDNA assay

## Key facts

- **NCT ID:** NCT07004413
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2031-01-01
- **Target enrollment:** 267 (ESTIMATED)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07004413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07004413, "Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07004413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*